STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting
STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3
STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022
20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting novel data on its lead program STC-15, a first-in-class clinical candidate, at the upcoming 34th EORTC-NCI-AACR (ENA) Molecular Targets and Cancer Therapeutics Symposium and the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting.
